U.S. Rep. Earl “Buddy” Carter (R-Ga.) recently led a bipartisan group of nearly a dozen U.S. House lawmakers in introducing [...] …
Category: General
The U.S. House Committee that oversees federal 340B policy today enacted a series of personnel shakeups, including the new chair [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The U.S. Supreme Court this week greenlit the Trump administration’s plans for massive layoffs and a reorganization at the U.S. [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A Virginia Republican is set to replace longtime 340B critic U.S. Rep. Earl “Buddy” Carter (R-Ga.) as the chair of [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Five major drugmakers recently announced new contract pharmacy restriction exemptions for 340B covered entities located in South Dakota and other [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
Whether it’s new manufacturer restrictions affecting script and data qualification, amended state laws or regulations, or updated audit guidelines, the 340B landscape is constantly evolving. So, it’s no surprise that managing an organization’s 340B program is not easy
…
The New York State Assembly recently honored longtime pharmacy leader and 340B advocate Mark Malahosky with a resolution commemorating his [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Hospital and health care provider advocates this week once again urged federal lawmakers to reject a controversial GOP-backed reconciliation plan [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The head of a key U.S. House subcommittee that oversees 340B drug pricing program policy issues is leaving the chairmanship [...] …